O	O	0	8	Defining	Define	B-VP	VBG	O	12	VMOD	O
O	O	9	20	therapeutic	therapeutic	B-NP	JJ	O	3	NMOD	O
O	O	21	28	targets	target	I-NP	NNS	O	1	OBJ	O
O	O	29	31	by	by	B-PP	IN	O	1	VMOD	O
O	O	32	37	using	use	B-VP	VBG	O	4	PMOD	O
O	O	38	48	adenovirus	adenovirus	B-NP	NN	O	5	OBJ	O
O	O	48	49	:	:	O	:	O	1	P	O
O	O	50	58	blocking	block	B-VP	VBG	O	12	SUB	O
T8	B-Entity	59	61	NF	NF	B-NP	NN	B-protein	11	NMOD	B-protein
T8	I-Entity	61	62	-	-	O	HYPH	I-protein	11	NMOD	I-protein
T8	I-Entity	62	68	kappaB	kappaB	B-NP	NN	I-protein	8	OBJ	I-protein
O	O	69	77	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	O
O	O	78	82	both	both	O	CC	O	17	NMOD	O
O	O	83	95	inflammatory	inflammatory	B-NP	JJ	O	17	NMOD	O
O	O	96	99	and	and	I-NP	CC	O	17	NMOD	O
O	O	100	111	destructive	destructive	I-NP	JJ	O	17	NMOD	O
O	O	112	122	mechanisms	mechanism	I-NP	NNS	O	12	OBJ	O
O	O	123	125	in	in	B-PP	IN	O	12	VMOD	O
O	O	126	136	rheumatoid	rheumatoid	B-NP	JJ	O	20	NMOD	O
O	O	137	145	synovium	synovium	I-NP	NN	O	18	PMOD	O
O	O	146	149	but	but	O	CC	O	12	VMOD	O
O	O	150	156	spares	spar	B-VP	VBZ	O	12	VMOD	O
O	O	157	161	anti	anti	B-NP	AFX	O	26	NMOD	O
O	O	161	162	-	-	I-NP	HYPH	O	26	NMOD	O
O	O	162	174	inflammatory	inflammatory	I-NP	JJ	B-protein	26	NMOD	B-protein
O	O	175	184	mediators	mediator	I-NP	NNS	I-protein	22	OBJ	I-protein
O	O	184	185	.	.	O	.	O	12	P	O

O	O	187	190	The	The	B-NP	DT	O	2	NMOD	O
O	O	191	195	role	role	I-NP	NN	O	16	SUB	O
O	O	196	198	of	of	B-PP	IN	O	2	NMOD	O
O	O	199	202	the	the	B-NP	DT	O	9	NMOD	O
O	O	203	216	transcription	transcription	I-NP	NN	B-protein	6	NMOD	B-protein
O	O	217	223	factor	factor	I-NP	NN	I-protein	9	NMOD	I-protein
T9	B-Entity	224	226	NF	NF	I-NP	NN	B-protein	9	NMOD	B-protein
T9	I-Entity	226	227	-	-	B-NP	HYPH	I-protein	9	NMOD	I-protein
T9	I-Entity	227	233	kappaB	kappaB	I-NP	NN	I-protein	3	PMOD	I-protein
O	O	234	236	in	in	B-PP	IN	O	2	NMOD	O
O	O	237	240	the	the	B-NP	DT	O	12	NMOD	O
O	O	241	253	pathogenesis	pathogenesis	I-NP	NN	O	10	PMOD	O
O	O	254	256	of	of	B-PP	IN	O	12	NMOD	O
O	O	257	267	rheumatoid	rheumatoid	B-NP	JJ	O	15	NMOD	O
O	O	268	277	arthritis	arthritis	I-NP	NN	O	13	PMOD	O
O	O	278	281	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	282	286	long	long	I-VP	RB	O	16	VMOD	O
O	O	287	291	been	be	I-VP	VBN	O	16	VC	O
O	O	292	293	a	a	B-NP	DT	O	20	NMOD	O
O	O	294	301	subject	subject	I-NP	NN	O	18	PRD	O
O	O	302	304	of	of	B-PP	IN	O	20	NMOD	O
O	O	305	316	controversy	controversy	B-NP	NN	O	21	PMOD	O
O	O	316	317	.	.	O	.	O	16	P	O

O	O	318	320	We	We	B-NP	PRP	O	2	SUB	O
O	O	321	325	used	use	B-VP	VBD	O	0	ROOT	O
O	O	326	328	an	an	B-NP	DT	O	5	NMOD	O
O	O	329	339	adenoviral	adenoviral	I-NP	JJ	O	5	NMOD	O
O	O	340	349	technique	technique	I-NP	NN	O	2	OBJ	O
O	O	350	352	of	of	B-PP	IN	O	5	NMOD	O
O	O	353	361	blocking	block	B-VP	VBG	O	6	PMOD	O
T10	B-Entity	362	364	NF	NF	B-NP	NN	B-protein	10	NMOD	B-protein
T10	I-Entity	364	365	-	-	B-NP	HYPH	I-protein	10	NMOD	I-protein
T10	I-Entity	365	371	kappaB	kappaB	I-NP	NN	I-protein	7	OBJ	I-protein
O	O	372	379	through	through	B-PP	IN	O	2	VMOD	O
O	O	380	394	overexpression	overexpression	B-NP	NN	O	11	PMOD	O
O	O	395	397	of	of	B-PP	IN	O	12	NMOD	O
O	O	398	401	the	the	B-NP	DT	O	17	NMOD	O
O	O	402	412	inhibitory	inhibitory	I-NP	JJ	B-protein	17	NMOD	B-protein
O	O	413	420	subunit	subunit	I-NP	NN	I-protein	17	NMOD	I-protein
T1	B-Protein	421	433	IkappaBalpha	IkappaBalpha	I-NP	NN	B-protein	13	PMOD	B-protein
O	O	433	434	,	,	O	,	O	17	P	O
O	O	435	440	which	which	B-NP	WDT	O	17	NMOD	O
O	O	441	444	has	have	B-VP	VBZ	O	19	SBAR	O
O	O	445	448	the	the	B-NP	DT	O	22	NMOD	O
O	O	449	458	advantage	advantage	I-NP	NN	O	20	OBJ	O
O	O	459	463	that	that	B-NP	IN	O	22	NMOD	O
O	O	464	466	it	it	B-NP	PRP	O	25	SUB	O
O	O	467	470	can	can	B-VP	MD	O	23	SBAR	O
O	O	471	473	be	be	I-VP	VB	O	25	VC	O
O	O	474	478	used	use	I-VP	VBN	O	26	VC	O
O	O	479	481	in	in	B-PP	IN	O	27	VMOD	O
O	O	482	485	the	the	B-NP	DT	O	31	NMOD	O
O	O	486	494	diseased	diseased	I-NP	JJ	O	31	NMOD	O
O	O	495	501	tissue	tissue	I-NP	NN	O	32	NMOD	O
O	O	502	508	itself	itself	B-NP	PRP	O	28	PMOD	O
O	O	508	509	,	,	O	,	O	27	P	O
O	O	510	514	with	with	B-PP	IN	O	27	VMOD	O
O	O	515	516	>	>	B-NP	JJR	O	37	NMOD	O
O	O	516	518	90	90	I-NP	CD	O	37	NMOD	O
O	O	518	519	%	%	I-NP	NN	O	34	PMOD	O
O	O	520	522	of	of	B-PP	IN	O	37	NMOD	O
O	O	523	526	the	the	B-NP	DT	O	47	NMOD	O
O	O	527	535	synovial	synovial	I-NP	JJ	B-cell_type	41	NMOD	B-cell_type
O	O	536	547	macrophages	macrophage	I-NP	NNS	I-cell_type	47	NMOD	I-cell_type
O	O	547	548	,	,	O	,	O	47	P	O
O	O	549	560	fibroblasts	fibroblast	B-NP	NNS	B-cell_type	47	NMOD	B-cell_type
O	O	560	561	,	,	O	,	O	47	P	O
O	O	562	565	and	and	O	CC	O	47	NMOD	O
O	O	566	567	T	T	B-NP	NN	B-cell_type	47	NMOD	B-cell_type
O	O	568	573	cells	cell	B-NP	NNS	I-cell_type	38	PMOD	I-cell_type
O	O	574	582	infected	infect	B-VP	VBN	O	47	NMOD	O
O	O	582	583	.	.	O	.	O	2	P	O

O	O	584	586	We	We	B-NP	PRP	O	2	SUB	O
O	O	587	592	found	find	B-VP	VBD	O	0	ROOT	O
O	O	593	597	that	that	B-SBAR	IN	O	2	VMOD	O
O	O	598	601	the	the	B-NP	DT	O	6	NMOD	O
O	O	602	613	spontaneous	spontaneous	I-NP	JJ	O	6	NMOD	O
O	O	614	624	production	production	I-NP	NN	O	18	SUB	O
O	O	625	627	of	of	B-PP	IN	O	6	NMOD	O
T2	B-Protein	628	633	tumor	tumor	B-NP	NN	B-protein	11	NMOD	B-protein
T2	I-Protein	634	642	necrosis	necrosis	I-NP	NN	I-protein	11	NMOD	I-protein
T2	I-Protein	643	649	factor	factor	I-NP	NN	I-protein	11	NMOD	I-protein
T2	I-Protein	650	655	alpha	alpha	I-NP	NN	I-protein	13	NMOD	I-protein
O	O	656	659	and	and	O	CC	O	13	NMOD	O
O	O	660	665	other	other	B-NP	JJ	O	7	PMOD	O
O	O	666	669	pro	pro	I-NP	AFX	B-protein	17	NMOD	B-protein
O	O	669	670	-	-	I-NP	HYPH	I-protein	17	NMOD	I-protein
O	O	670	682	inflammatory	inflammatory	I-NP	JJ	I-protein	17	NMOD	I-protein
O	O	683	692	cytokines	cytokine	I-NP	NNS	I-protein	13	NMOD	I-protein
O	O	693	695	is	be	B-VP	VBZ	O	3	SBAR	O
T11	B-Entity	696	698	NF	NF	B-NP	NN	B-protein	21	NMOD	B-protein
T11	I-Entity	698	699	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
T11	I-Entity	699	705	kappaB	kappaB	I-NP	NN	I-protein	18	PRD	I-protein
O	O	705	706	-	-	B-VP	HYPH	O	21	P	O
O	O	706	715	dependent	dependent	B-ADJP	JJ	O	21	NMOD	O
O	O	716	718	in	in	B-PP	IN	O	23	AMOD	O
O	O	719	729	rheumatoid	rheumatoid	B-NP	JJ	O	27	NMOD	O
O	O	730	738	synovial	synovial	I-NP	JJ	O	27	NMOD	O
O	O	739	745	tissue	tissue	I-NP	NN	O	24	PMOD	O
O	O	745	746	,	,	O	,	O	18	P	O
O	O	747	749	in	in	B-PP	IN	O	18	VMOD	O
O	O	750	758	contrast	contrast	B-NP	NN	O	29	PMOD	O
O	O	759	761	to	to	B-PP	TO	O	30	NMOD	O
O	O	762	765	the	the	B-NP	DT	O	37	NMOD	O
O	O	766	770	main	main	I-NP	JJ	O	37	NMOD	O
O	O	771	775	anti	anti	I-NP	AFX	O	37	NMOD	O
O	O	775	776	-	-	I-NP	HYPH	O	37	NMOD	O
O	O	776	788	inflammatory	inflammatory	I-NP	JJ	B-protein	37	NMOD	B-protein
O	O	789	798	mediators	mediator	I-NP	NNS	I-protein	31	PMOD	I-protein
O	O	798	799	,	,	O	,	O	18	P	O
O	O	800	804	like	like	B-PP	IN	O	18	VMOD	O
T3	B-Protein	805	807	IL	IL	B-NP	NN	B-protein	45	NMOD	B-protein
T3	I-Protein	807	808	-	-	O	HYPH	I-protein	45	NMOD	I-protein
T3	I-Protein	808	810	10	10	B-NP	CD	I-protein	45	NMOD	I-protein
O	O	811	814	and	and	I-NP	CC	O	45	NMOD	O
T4	B-Protein	815	816	-	-	I-NP	SYM	O	45	NMOD	O
T4	I-Protein	816	818	11	11	I-NP	CD	O	39	PMOD	O
O	O	818	819	,	,	O	,	O	53	P	O
O	O	820	823	and	and	O	CC	O	53	NMOD	O
O	O	824	827	the	the	B-NP	DT	O	53	NMOD	O
O	O	828	830	IL	IL	I-NP	NN	B-protein	53	NMOD	B-protein
O	O	830	831	-	-	B-NP	HYPH	I-protein	53	NMOD	I-protein
O	O	831	832	1	1	I-NP	CD	I-protein	53	NMOD	I-protein
O	O	833	841	receptor	receptor	I-NP	NN	I-protein	53	NMOD	I-protein
O	O	842	852	antagonist	antagonist	I-NP	NN	O	18	PRD	O
O	O	852	853	.	.	O	.	O	2	P	O

O	O	854	856	Of	Of	B-PP	IN	O	8	VMOD	O
O	O	857	861	even	even	B-NP	RB	O	3	AMOD	O
O	O	862	866	more	more	I-NP	JJR	O	4	NMOD	O
O	O	867	875	interest	interest	I-NP	NN	O	1	PMOD	O
O	O	875	876	,	,	O	,	O	8	P	O
T5	B-Protein	877	889	IkappaBalpha	IkappaBalpha	B-NP	NN	B-protein	7	NMOD	B-protein
O	O	890	904	overexpression	overexpression	I-NP	NN	O	8	SUB	O
O	O	905	914	inhibited	inhibit	B-VP	VBD	O	0	ROOT	O
O	O	915	918	the	the	B-NP	DT	O	10	NMOD	O
O	O	919	929	production	production	I-NP	NN	O	8	OBJ	O
O	O	930	932	of	of	B-PP	IN	O	10	NMOD	O
T6	B-Protein	933	939	matrix	matrix	B-NP	NN	B-protein	13	NMOD	B-protein
T6	I-Protein	940	958	metalloproteinases	metalloproteinas	I-NP	NNS	I-protein	11	PMOD	I-protein
T6	I-Protein	959	960	1	1	I-NP	CD	I-protein	16	NMOD	I-protein
O	O	961	964	and	and	I-NP	CC	I-protein	16	NMOD	I-protein
T7	B-Protein	965	966	3	3	I-NP	CD	I-protein	13	NMOD	I-protein
O	O	967	972	while	while	B-SBAR	IN	O	8	VMOD	O
O	O	973	976	not	not	B-VP	RB	O	19	VMOD	O
O	O	977	986	affecting	affect	I-VP	VBG	O	17	SBAR	O
O	O	987	992	their	their	B-NP	PRP$	O	22	NMOD	O
O	O	993	999	tissue	tissue	I-NP	NN	O	22	NMOD	O
O	O	1000	1009	inhibitor	inhibitor	I-NP	NN	O	19	OBJ	O
O	O	1009	1010	.	.	O	.	O	8	P	O

O	O	1011	1019	Blocking	Block	B-VP	VBG	O	10	SUB	O
T12	B-Entity	1020	1022	NF	NF	B-NP	NN	B-protein	4	NMOD	B-protein
T12	I-Entity	1022	1023	-	-	O	HYPH	I-protein	4	NMOD	I-protein
T12	I-Entity	1023	1029	kappaB	kappaB	B-NP	NN	I-protein	1	OBJ	I-protein
O	O	1030	1032	in	in	B-PP	IN	O	1	VMOD	O
O	O	1033	1036	the	the	B-NP	DT	O	8	NMOD	O
O	O	1037	1047	rheumatoid	rheumatoid	I-NP	JJ	O	8	NMOD	O
O	O	1048	1053	joint	joint	I-NP	NN	O	5	PMOD	O
O	O	1054	1058	thus	thus	B-ADVP	RB	O	1	VMOD	O
O	O	1059	1062	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	1063	1064	a	a	B-NP	DT	O	14	NMOD	O
O	O	1065	1069	very	very	I-NP	RB	O	13	AMOD	O
O	O	1070	1080	beneficial	beneficial	I-NP	JJ	O	14	NMOD	O
O	O	1081	1088	profile	profile	I-NP	NN	O	10	OBJ	O
O	O	1088	1089	,	,	O	,	O	10	P	O
O	O	1090	1098	reducing	reduce	B-VP	VBG	O	10	VMOD	O
O	O	1099	1103	both	both	O	CC	O	24	NMOD	O
O	O	1104	1107	the	the	B-NP	DT	O	20	NMOD	O
O	O	1108	1120	inflammatory	inflammatory	I-NP	JJ	O	20	NMOD	O
O	O	1121	1129	response	response	I-NP	NN	O	24	NMOD	O
O	O	1130	1133	and	and	O	CC	O	24	NMOD	O
O	O	1134	1137	the	the	B-NP	DT	O	24	NMOD	O
O	O	1138	1144	tissue	tissue	I-NP	NN	O	24	NMOD	O
O	O	1145	1156	destruction	destruction	I-NP	NN	O	16	OBJ	O
O	O	1156	1157	.	.	O	.	O	10	P	O

O	O	1158	1161	The	The	B-NP	DT	O	3	NMOD	O
O	O	1162	1172	adenoviral	adenoviral	I-NP	JJ	O	3	NMOD	O
O	O	1173	1182	technique	technique	I-NP	NN	O	6	SUB	O
O	O	1183	1192	described	describe	B-VP	VBN	O	3	NMOD	O
O	O	1193	1197	here	here	B-ADVP	RB	O	4	VMOD	O
O	O	1198	1201	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	1202	1212	widespread	widespread	B-NP	JJ	O	8	NMOD	O
O	O	1213	1226	applicability	applicability	I-NP	NN	O	6	OBJ	O
O	O	1226	1227	,	,	O	,	O	6	P	O
O	O	1228	1236	allowing	allow	B-VP	VBG	O	6	VMOD	O
O	O	1237	1242	rapid	rapid	B-NP	JJ	O	12	NMOD	O
O	O	1243	1250	testing	testing	I-NP	NN	O	10	OBJ	O
O	O	1251	1253	of	of	B-PP	IN	O	12	NMOD	O
O	O	1254	1257	the	the	B-NP	DT	O	15	NMOD	O
O	O	1258	1265	effects	effect	I-NP	NNS	O	13	PMOD	O
O	O	1266	1268	of	of	B-PP	IN	O	15	NMOD	O
O	O	1269	1277	blocking	block	B-VP	VBG	O	16	PMOD	O
O	O	1278	1279	a	a	B-NP	DT	O	21	NMOD	O
O	O	1280	1289	potential	potential	I-NP	JJ	O	21	NMOD	O
O	O	1290	1301	therapeutic	therapeutic	I-NP	JJ	O	21	NMOD	O
O	O	1302	1308	target	target	I-NP	NN	O	17	OBJ	O
O	O	1309	1311	in	in	B-PP	IN	O	17	VMOD	O
O	O	1312	1318	either	either	B-NP	DT	O	24	NMOD	O
O	O	1319	1327	cultures	culture	I-NP	NNS	O	22	PMOD	O
O	O	1328	1330	of	of	B-PP	IN	O	24	NMOD	O
O	O	1331	1337	normal	normal	B-NP	JJ	B-cell_type	27	NMOD	B-cell_type
O	O	1338	1343	cells	cell	I-NP	NNS	I-cell_type	25	PMOD	I-cell_type
O	O	1344	1346	or	or	B-PP	CC	O	22	PMOD	O
O	O	1347	1349	in	in	B-PP	IN	O	22	PMOD	O
O	O	1350	1353	the	the	B-NP	DT	O	32	NMOD	O
O	O	1354	1362	diseased	diseased	I-NP	JJ	O	32	NMOD	O
O	O	1363	1369	tissue	tissue	I-NP	NN	O	33	NMOD	O
O	O	1370	1376	itself	itself	B-NP	PRP	O	29	PMOD	O
O	O	1376	1377	.	.	O	.	O	6	P	O
